Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease

Trial Profile

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 14 Apr 2019 Status changed from active, no longer recruiting to completed.
  • 29 Oct 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2016.
  • 29 Oct 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top